N-Tert-butyl-N-propylprop-2-enamide | 116389-86-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-Tert-butyl-N-propylprop-2-enamide
• 英文别名: N-tert-butyl-N-propylprop-2-enamide
• CAS: 116389-86-7
• 化学式: C₁₀H₁₉NO
• 分子量: 169.26
• InChiKey: OKEXKQIUYJPVNQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  12
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.7
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• COVALENT INHIBITORS OF KRAS G12C
  申请人：Araxes Pharma LLC

  公开号：US20140288045A1

  公开（公告）日：2014-09-25

  Irreversible inhibitors of G12C mutant K-Ras protein are provided. Also disclosed are methods to modulate the activity of G12C mutant K-Ras protein and methods of treatment of disorders mediated by G12C mutant K-Ras protein.

  G12C突变K-Ras蛋白的不可逆抑制剂已提供。还公开了调节G12C突变K-Ras蛋白活性的方法以及通过G12C突变K-Ras蛋白介导的疾病治疗方法。
• INHIBITORS OF KRAS G12C
  申请人：Araxes Pharma LLC

  公开号：US20150239900A1

  公开（公告）日：2015-08-27

  Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I): or a pharmaceutically acceptable salt, tautomer, prodrug or stereoisomer thereof, wherein R 1 , R 2a , R 3a , R 3b , R 4a , R 4b , G 1 , G 2 , L 1 , L 2 , m 1 , m 2 , A, B, W, X, Y, Z and E are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, are also provided.

  提供了具有抑制G12C突变KRAS蛋白活性的化合物。这些化合物具有以下结构（I）：或其药学上可接受的盐、互变异构体、前药或立体异构体，其中R1、R2a、R3a、R3b、R4a、R4b、G1、G2、L1、L2、m1、m2、A、B、W、X、Y、Z和E的定义如本文所述。还提供了与制备和使用这些化合物相关的方法，包括含有这些化合物的制药组合物以及用于治疗癌症等疾病的调节G12C突变KRAS蛋白活性的方法。
• INHIBITORS OF KRAS G12C MUTANT PROTEINS
  申请人：Araxes Pharma LLC

  公开号：US20160108019A1

  公开（公告）日：2016-04-21

  Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I): or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof, wherein R 1 , R 2 , R 3a , R 3b , R 4a , R 4b , G 1 , G 2 , L, m 1 , m 2 and E are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, are also provided.

  提供了作为G12C突变KRAS蛋白抑制剂活性的化合物。该化合物具有以下结构（I）：或其药学上可接受的盐、互变异构体、立体异构体或前药，其中R1、R2、R3a、R3b、R4a、R4b、G1、G2、L、m1、m2和E的定义如本文所述。还提供了与制备和使用这种化合物相关的方法，包括包含这种化合物的制药组合物以及用于治疗癌症等疾病的调节G12C突变KRAS蛋白活性的方法。
• Methods and compositions for inhibition of Ras
  申请人：ARAXES PHARMA LLC

  公开号：US10011600B2

  公开（公告）日：2018-07-03

  Inhibitors of Ras protein, methods to modulate the activity of Ras protein, and methods of treatment of disorders mediated by Ras protein are provided. A method for regulating activity of a K-Ras, H-Ras or N-Ras mutant protein with a compound is described. Disorders that can be treated include cancer, such as hematological cancer, pancreatic cancer, MYH associated polyposis, colorectal cancer, or lung cancer.

  提供了 Ras 蛋白的抑制剂、调节 Ras 蛋白活性的方法以及治疗由 Ras 蛋白介导的疾病的方法。描述了一种用化合物调节 K-Ras、H-Ras 或 N-Ras 突变蛋白活性的方法。可治疗的疾病包括癌症，如血癌、胰腺癌、MYH 相关性息肉病、结直肠癌或肺癌。
• SUBSTITUTED QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF
  申请人：Araxes Pharma LLC

  公开号：US20160297774A1

  公开（公告）日：2016-10-13

  Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have one of the following structures (I), (II) or (III): or a pharmaceutically acceptable salt, stereoisomer or prodrug thereof, wherein R 1 , R 2a , R 2b , R 2c , R 3a , R 3b , R 4a , R 4b , R 5a , R 5b , R 6 , A, B, G 1 , G 2 , L 1 , L 2 , m 1 , m 2 , n, x, y, X and E are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, are also provided.